Roche Venture Fund
Corporate VCBasel · Seed–Growth · 10 people tracked
Investment thesis
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
Source: firm website, verified Jul 29, 2026.
Team · 10 people
from the firm's website & curated & public directories
What they invest in
from 26 of 29 portfolio companiesBiotech ×25Healthtech ×18Medical Devices ×7Deep Tech ×4Digital Health ×3AI & Machine Learning ×1Impact & Social Good ×1
HQs:United States×14Spain×2France×2Denmark×1Italy×1
Investments · 29 tracked
founders shown can be your intro pathBy year:2021 · 22018 · 12017 · 12015 · 15 dated
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)Joe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)Helen Collins(Chief Medical Officer)Ben Hohl(Chief Financial Officer and Head of Corporate Development)
Co-investors5AM VenturesOrbiMedPfizer Venture InvestmentsARCH Venture Partners
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Nerissa Kreher(Executive Officer)Kory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNathan Dowden(Executive Officer)Natarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Co-investors5AM VenturesMPM BioImpactTCG CrossoverAgent Capital
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon
Riley Ennis(Co-Founder and Chief Product Officer)Charles Roberts(Director)inGabriel Otte(Director)in
BoardStuart Lawson(Director)
Co-investorsRA CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management CompanyAverin Capital+8 more
COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.
BiotechHealthtech
Co-investorsAlpha Wave GlobalLumira VenturesAngelini VenturesJDRF T1D Fund
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.
BiotechDeep TechDigital HealthHealthtechMarseille, FR
Benjamin Charles(Co-Founder & CEO)Patrick Collombat(Co-Founder & Scientific Advisor)inJean-Pascal Tranié(Co-Founder)in
Co-investorsAdBio partnersBoehringer Ingelheim Venture FundSunstone CapitalJDRF T1D Fund
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)
Co-investorsNovartis Venture FundSanofi VenturesYsios CapitalAsabys PartnersCriteria Bio VenturesNew Enterprise Associates (NEA)+2 more
Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.
BiotechHealthtechParis, FR
Co-investorsHealthCapKurma PartnersNovartis Venture FundYsios CapitalColumbus Venture PartnersEurazeo+1 more
BiotechWatertown, US
Edward Mascioli(Executive Officer)Andrew Myers(Director)
BoardMarkus Goebel(Director)Henry Skinner(Director)Vikas Goyal(Director)Raj Parekh(Director)in
Board seatAnja Harmeier· per SEC Form D · $20M raise · filed Mar 2018
Co-investorsAdvent Life Sciences
Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH.
BiotechHealthtechSouth San Francisco, US
Leonid Beigelman(President)inLawrence M. Blatt(Chairman, President & CEO (Co-founder))inHardean Achneck(Executive Officer)Sushmita Chanda(Executive Vice President - Preclinical Development)Brian Dowd(Executive Vice President - Controller)Lucinda Quan(Executive Vice President - General Counsel)
Co-investorsMPM BioVentures 2014Vivo Capital
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)
Co-investorsAlta PartnersNew Enterprise Associates (NEA)RiverVest Venture PartnersSamsara BioCapital
Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.
BiotechHealthtechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in
BoardSamuel Bjork(Director)inMonique Schiersing(Director)inJohn McKearn(Director)in
Co-investorsRiverVest Venture PartnersVivo Capital3x5 PartnersCodon CapitalDigitalis Ventures
Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.
BiotechHealthtechMilan, IT
Co-investorsSofinnova PartnersIndaco Venture PartnersAbbVieJDRF T1D Fund
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)Mitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)Alexandra Cantley(Director)Seiji Miyahara(Director)
Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundSamsara BioCapitalTaiho Ventures, LLC+3 more
Forcefield Therapeutics develops cardioprotective proteins for the treatment of cardiac disease, with an initial focus on myocardial infarction (heart attack).
BiotechHealthtechMedical Devices
John
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investors5AM VenturesCatalio Capital Management, LPLifeArc VenturesSixty Degree CapitalSofinnova PartnersAgent Capital+1 more
Portfolio company acquired by Roche.
BiotechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)Mitchell Mutz(Director)Nicholas Walrod(Director)
BoardJohn McKearn(Director)inKarl Handelsman(Director)
Co-investorsDigitalis VenturesRiverVest Venture Partners
The National Kidney Foundation works to eliminate preventable kidney disease, accelerate innovation in patient care, and address structural inequities in kidney treatment and transplantation services.
HealthtechImpact & Social Good
Co-investorsYsios CapitalBioGeneration VenturesEpidarex CapitalScottish National Investment BankSofinnova Partners
Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.
BiotechSan Diego, US
Yi Liu(Executive Officer, Director)Lynn Yang(Director)
BoardCarl Gordon(Director)in
Co-investorsEcoR1 CapitalOrbiMed
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
BiotechDeep TechHealthtechMedical DevicesMataró, ES
Marc Martinell(Co-Founder & Chief Executive Officer)
Co-investorsChiesi VenturesCriteria Bio VenturesFund+Invivo Capital PartnersKurma PartnersYsios Capital+1 more
Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases.
BiotechMedical Devices
Adele Rowley(Chief Scientific Officer)
Co-investorsEpidarex CapitalSofinnova PartnersBioGeneration VenturesScottish National Investment Bank
Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.
BiotechHealthtech
Co-investorsPfizer Venture InvestmentsSofinnova PartnersSR One Capital Management
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.
BiotechDeep TechHealthtechMedical DevicesAarhus, DK
Co-investorsJeito CapitalNovo HoldingsInkef
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)Volker Knappertz(Executive Vice President of Research & Development)Michael Samar(Chief Financial Officer)Rob Lasser(Chief Medical Officer)
Co-investorsBioMedPartnersJeito CapitalSofinnova PartnersEQTEQT Life SciencesForbion+2 more
BiotechPleasanton, US
Bill W. Colston, Ph.D.(Director)Klint Rose, Ph.D.(Chief Scientific Officer)Juan G. Santiago(Executive Officer, Director, Promoter)Klint Rose(Executive Officer, Director, Promoter)Amy Hiddessen(Executive Officer, Director, Promoter)Barney E. Saunders,Ph.D.(Chief Executive Officer)
Co-investors5AM VenturesCota Capital
Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions.
BiotechHealthtechCambridge, US
WILLIAM CIAMBRONE(Executive Officer)DOUGLAS S. INGRAM(Executive Officer, Director)DAVID TYRONNE HOWTON(Executive Officer)SANDESH MAHATME(Executive Officer)GILMORE O'NEILL(Executive Officer)ALEXANDER CUMBO(Executive Officer)
Co-investorsAvoro Capital Advisors
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.
BiotechHealthtechBrisbane, US
Stephen Brady(Director)Matthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)Thomas Woiwode(Director)Geoffrey Nichol(Director)Thomas W. Dubensky(Executive Officer, Director)
Co-investorsF-Prime CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Quan Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 4
IPOs and acquisitions across the tracked portfolioEnliven TherapeuticsNASDAQ: ELVNEntrada Therapeutics, Inc.NASDAQ: TRDAFreenomeNASDAQ: FRNMGood Therapeuticsacq. by Roche
Portfolio news
latest coverage across their companiesEnliven Therapeutics · tickerreport.com · Aug 21, 2026
Aligos Therapeutics · rttnews.com · Aug 10, 2026
Mironid · eu-startups.com · Aug 7, 2026
Kidney · eu-startups.com · Aug 7, 2026
Sarepta Therapeutics · finance.yahoo.com · Aug 1, 2026
Tempest Therapeutics · tipranks.com · Jul 22, 2026
Frequently asked questions
- How many investments has Roche Venture Fund made?
- Roche Venture Fund has 25 tracked investments.
- What stage does Roche Venture Fund invest at?
- Roche Venture Fund invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Roche Venture Fund's typical check size?
- Roche Venture Fund typically writes checks of $648K – $3.2M.
- What sectors does Roche Venture Fund focus on?
- Roche Venture Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices, Sector Agnostic.
- Where is Roche Venture Fund located?
- Roche Venture Fund is headquartered in Basel, CH.
- Who does Roche Venture Fund co-invest with?
- Roche Venture Fund most often shares deals with Sofinnova Partners, Novartis Venture Fund, Pfizer Venture Investments, among 52 tracked co-investors.
Media · Podcasts & interviews
featuring the team#OptimumTV with Anja Harmeier of Roche Venture Fund for #lifescience investor outlook on 2026
Optimum Strategic Communications · Anja Harmeier
Images
Co-investors · 23
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Ysios Capital is a life sciences investor that finances innovative biotech companies worldwide, providing resources to develop novel therapies for indications with high unmet medical needs.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Digitalis Ventures invests in solutions to unmet needs in biomedicine and health, backing biotechnology and technology-enabled companies across human health and animal health.
RiverVest Venture Partners is a life sciences venture capital firm that invests in biotechnology and medical companies, working with entrepreneurs to advance therapeutic and medical innovations.
BioGeneration Ventures is a venture capital firm that invests in early-stage biotech companies in Europe, with a focus on healthcare innovations.
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
▶11 more co-investors
InkefCodon CapitalAtlas VentureDeerfield Management CompanyMorgenthalerHatteras Venture PartnersOmega FundsLightstone VenturesApollo Health VenturesFaberWestlake Village BioPartners
Firms observed investing alongside Roche Venture Fund, from public investor directories. Shared companies are the overlap with Roche Venture Fund's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Innovestor is a Finnish investment manager active in venture capital, real estate, and energy storage, and also provides corporate venturing services.